Combined use of Alpha 2b Interferon and Chlorambucil in the Management of Previously Treated B-Cell Chronic Lymphocytic Leukemia

Abstract

We hereby here the successful use of a combined therapeutic approach with alpha 2b Interferon (IFN) and Chlorambucil in the management of previously treated B-cell chronic lymphocytic leukemia (B-CLL). The two patients under study had been managed with repeated and frequent cycles of Chlorambucil. Rather than with more toxic multidrug regimens, the hematological picture was controlled with 3 MU of IFN every three-five days and 5 mg of Chlorambucil every two—five days. Using such an approach, which is feasible on an out-patients basis and devoid of significant side effects, a consistent control of the WBC count was achieved for 32 and 16 months, respectively.

Key Words:

• Alpha 2b Interferon
• chlorambucil
• B-CLL